Journal of Cosmetology & Trichology

ISSN: 2471-9323

Open Access

Shoban Babu Varhtya

Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India

  • Mini Review   
    Risankizumab (Skyrizi®) in Moderate to Severe Psoriasis: A Mini Review
    Author(s): Shoban Babu Varhtya*

    Psoriasis is an autoimmune disease that affects nearly about 2%-3% of population across the globe. Role of biologics in moderate to severe psoriasis increased after observing efficacy of TNF-alpha antagonist such as etanercept, infliximab. The USFDA approved risankizumab in 2019 in the treatment of moderate to severe plaque psoriasis. This drug targets interleukin-23 (IL-23 by binding to its subcomponent, the protein p19. The results of landmark trials UltIMMa-1 and UltIMMa-2, IMMvent, IMMerge and IMMhance along with SustaIMM is a phase II/III trial shows that risankizumab effective at 150 mg every 12 weeks after initial two doses at week-0 and 4. Improvement of disease activity measured as PASI 90/ sPGA 0/1 or other outcomes favors risankizumab over placebo or adalimumab or ustekinumab at week 16 and 52. Long-term follow-up findings also consistent with its earlier outcomes. Risankiz.. Read More»

    Abstract HTML PDF

arrow_upward arrow_upward